Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00009802 · ClinicalTrials.gov registry record · Phase 1

Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors

A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by University of Pittsburgh.

Completed
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT00009802: Completed Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, sponsored by University of Pittsburgh.

NCT00009802 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by University of Pittsburgh. The registered enrollment target is 45 participants, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00009802, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining calcitriol with paclitaxel in treating patients who have advanced solid tumors.

Interventions

  • DRUG paclitaxel
  • DIETARY_SUPPLEMENT calcitriol

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Cancer Institute - Pittsburgh

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 1998-06
Est. Completion 2005-06
Phase Phase 1
University of Pittsburgh

1,238 total trials

What the finished NCT00009802 record still lists

NCT00009802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 501-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.

NCT00009802 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00009802 about?

NCT00009802 is a clinical study titled "Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining calcitriol...

What is the current status of trial NCT00009802?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 1998-06. Estimated completion is 2005-06.

What conditions does trial NCT00009802 study?

This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific.

What interventions are being tested in trial NCT00009802?

The interventions under investigation include: paclitaxel (DRUG), calcitriol (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00009802?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00009802 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Unspecified Adult Solid Tumor, Protocol Specific

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00009802's enrollment target sits among peer trials

45 35th of 83 higher than 48 of 83 other Unspecified Adult Solid Tumor, Protocol Specific trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Unspecified Adult Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00009802, the US trial registry maintained by the National Library of Medicine. NCT00009802 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.